Clinical Pharmacokinetics

, Volume 28, Issue 4, pp 327–342 | Cite as

Pharmacokinetic Optimisation of Vancomycin Therapy

  • W. Greg Leader
  • Mary H. H. Chandler
  • Mary Castiglia
Review Article Pharmacokinetics-Therapeutics

Summary

Renewed interest in vancomycin over the past decade has led to an abundance of data concerning the pharmacokinetics of vancomycin, and its dosage selection and concentration-response relationships.

No definitive data exist that correlate vancomycin serum concentrations with clinical outcomes. However, inconsistencies in sampling times for peak serum concentrations and differences in infusion times make interpreting vancomycin serum concentrations difficult. Furthermore, the evidence implicating vancomycin as a cause of oto- or nephrotoxicity is circumstantial, and these adverse effects may occur only in high-risk populations.

Owing to the variability in its dose-serum concentration relationship and multicompartmental pharmacokinetics, several methodologies have been developed for instituting and adjusting vancomycin dosages. Nomograms rely on a fixed volume of distribution and the relationship between vancomycin clearance and creatinine clearance. Since both of these factors may be altered in certain populations, dosage methodologies (both traditional and Bayesian) that use population- or patient-specific pharmacokinetic data perform better than standard nomograms for initiating vancomycin therapy. Controversy still exists as to whether a 1- or a 2-compartment model is more appropriate for making dosage adjustments; however, steady-state rather than non-steady-state vancomycin serum concentrations should be used for dosage adjustments. Certain pathophysiological states such as age, bodyweight and renal function contribute to altered pharmacokinetics and may alter the design of the dosage regimen.

Since no definitive relationship exists between vancomycin serum concentrations and either clinical outcome or adverse effects, considerable controversy surrounds the utility of monitoring serum vancomycin concentrations. Therefore, routine vancomycin serum concentration monitoring may be warranted only in specific populations, such as patients receiving concurrent aminoglycoside therapy or those receiving higher than usual dosages of vancomycin, patients undergoing haemodialysis and patients with rapidly changing renal function.

Keywords

Vancomycin Adis International Limited Antimicrob Agent Elimination Rate Constant Serum Drug Concentration 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Wilhelm MR. Vancomycin. Mayo Clin Proc 1991; 66: 1165–70PubMedGoogle Scholar
  2. 2.
    Pryka RD, Rodvold KA, Erdman SM. An updated comparison of drug dosing methods. Part IV: vancomycin clinical pharmacokinetics. Clin Pharmacokinet 1991; 20: 463–76PubMedCrossRefGoogle Scholar
  3. 3.
    Levine DP, Cushing RD, Jui J, et al. Community-acquired methicillin-resistant Staphylococcus aureus endocarditis in the Detroit Medical Center. Ann Intern Med 1982; 97: 330–8PubMedGoogle Scholar
  4. 4.
    Small PM, Chambers HE. Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. Antimicrob Agents Chemother 1990; 34: 1227–31PubMedCrossRefGoogle Scholar
  5. 5.
    Rodvold KA. Therapeutic considerations for infections caused by Staphylococcus epidermitis. Pharmacotherapy 1988; 8 (Suppl.): 14S–8SPubMedGoogle Scholar
  6. 6.
    Peetermans WE, Hoogeterp JJ, Hazekamp-Van Dokkum AM, et al. Antistaphylococcal activities of teicoplanin and vancomycin in vitro and in an experimental infection. Antimicrob Agents Chemother 1990; 34: 1869–74PubMedCrossRefGoogle Scholar
  7. 7.
    Ackerman BH, Vannier AM, Eudy EB. Analysis of vancomycin time-kill studies with Staphylococcus species by using a curve stripping program to describe the relationship between concentration and pharmacodynamic response. Antimicrob Agents Chemother 1992; 36: 1766–9PubMedCrossRefGoogle Scholar
  8. 8.
    Healy DP, Polk RE, Garson ML, et al. Comparison of steady state pharmacokinetics of two dosage regimens of vancomycin in normal volunteers. Antimicrob Agents Chemother 1987; 31: 393–7PubMedCrossRefGoogle Scholar
  9. 9.
    Louria DB, Kaminski T, Buchman J. Vancomycin in severe staphylococcal infections. Arch Intern Med 1961; 107: 225–40PubMedCrossRefGoogle Scholar
  10. 10.
    Sorrell TC, Packham DR, Shanker S, et al. Vancomycin therapy for methicillin-resistant Staphylococcus aureus. Ann Intern Med 1982; 97: 344–50PubMedGoogle Scholar
  11. 11.
    Schaad UB, McCracken Jr GH, Nelson JD. Clinical pharmacology and efficacy of vancomycin in pediatric patients. J Pediatr 1980; 96: 119–26PubMedCrossRefGoogle Scholar
  12. 12.
    Lisby-Sutch SM, Nahata MC. Dosage guidelines for the use of vancomycin based on its pharmacokinetics in infants. Eur J Clin Pharmacol 1988; 35: 637–42PubMedCrossRefGoogle Scholar
  13. 13.
    Viladrich PF, Gudiol F, Liñares J, et al. Evaluation of vancomycin for therapy of adult pneumococcal meningitis. Antimicrob Agents Chemother 1991; 35: 2467–72PubMedCrossRefGoogle Scholar
  14. 14.
    Cafferkey MT, Hone R, Keane CT. Severe staphylococcal infections treated with vancomycin. J Antimicrob Chemother 1982; 9: 69–74PubMedCrossRefGoogle Scholar
  15. 15.
    Woodley DW, Hall WH. The treatment of severe staphylococcal infections with vancomycin. Ann Intern Med 1961; 55: 235–49PubMedGoogle Scholar
  16. 16.
    Dutton AAC, Elmes PC. Vancomycin: report on treatment of patients with severe staphylococcal infections. BMJ 1959; 1: 1144–9PubMedCrossRefGoogle Scholar
  17. 17.
    Cony-Makhoul P, Brossard G, Marit G, et al. A prospective study comparing vancomycin and teicoplanin as second-line empiric therapy for infection in neutropenic patients. Br J Haematol 1990; 76 Suppl. 2: 35–40PubMedCrossRefGoogle Scholar
  18. 18.
    Anaissie EJ, Fainstein V, Bodey GP, et al. Randomized trial of beta-lactam regimens in febrile neutropenic cancer patients. Am J Med 1988; 84: 581–9PubMedCrossRefGoogle Scholar
  19. 19.
    Jones P, Rolston K, Fainstein V, et al. Aztreonam plus vancomycin (plus amikacin) vs. moxalactam plus ticarcillin for the empiric treatment of febrile episodes in neutropenic cancer patients. Rev Infect Dis 1985; 7 Suppl. 4: S741–6PubMedCrossRefGoogle Scholar
  20. 20.
    Brummett RE, Fox KE, Jacobs F, et al. Augmented gentamicin ototoxicity induced by vancomycin in guinea pigs. Arch Otolaryngol Head Neck Surg 1990; 116: 61–4PubMedCrossRefGoogle Scholar
  21. 21.
    Tange RA, Keiviet HL, Marie JV, et al. An experimental study of vancomycin-induced cochlear damage. Arch Otorhinolaryngol 1989; 246: 67–70PubMedCrossRefGoogle Scholar
  22. 22.
    Lutz H, Lenarz T, Weidauer H, et al. Ototoxicity of vancomycin: an experimental study in guinea pigs. ORL J Otorhinolaryngol Relat Spec 1991; 53: 273–8PubMedCrossRefGoogle Scholar
  23. 23.
    Aronoff GR, Sloan RS, Dinwiddie Jr CB, et al. Effects of vancomycin on renal function in rats. Antimicrob Agents Chemother 1981; 19: 306–8PubMedCrossRefGoogle Scholar
  24. 24.
    Wold JS, Turnipseed SA. Toxicology of vancomycin in laboratory animals. Rev Infect Dis 1981; 3 Suppl.: S224–9PubMedGoogle Scholar
  25. 25.
    Matzke GR, Zhanel GG, Guay DRP. Clinical pharmacokinetics of vancomycin. Clin Pharmacokinet 1986; 11: 257–82PubMedCrossRefGoogle Scholar
  26. 26.
    Traber PG, Levine DP. Vancomycin ototoxicity in a patient with normal renal function. Ann Intern Med 1981; 95: 458–60PubMedGoogle Scholar
  27. 27.
    Ahmad R, Raichura N, Kilbane V, et al. Vancomycin: a reappraisal [letter]. BMJ 1982; 284: 1953–4PubMedCrossRefGoogle Scholar
  28. 28.
    Mellor JA, Kingdom J, Cafferkey M, et al. Vancomycin toxicity: a prospective study. J Antimicrob Chemother 1985; 15: 773–80PubMedCrossRefGoogle Scholar
  29. 29.
    Mellor JA, Kingdom J, Cafferkey M, et al. Vancomycin ototoxicity in patients with normal renal function. Br J Audiol 1984; 18: 179–80PubMedCrossRefGoogle Scholar
  30. 30.
    Morris AJ, Bilinsky RT. Prevention of staphylococcal shunt infections by continuous vancomycin prophylaxis. Am J Med Sci 1971; 262: 87–92PubMedCrossRefGoogle Scholar
  31. 31.
    Hook EW, Johnson WD. Vancomycin therapy of bacterial endocarditis. Am J Med 1978; 65: 411–5PubMedCrossRefGoogle Scholar
  32. 32.
    Geraci JE, Heilman FR, Nichols DR, et al. Antibiotic therapy of bacterial endocarditis. VII: vancomycin for acute micrococcal endocarditis. Mayo Clin Proc 1958; 33: 172–81Google Scholar
  33. 33.
    Kirby WMM, Perry DM, Bauer AW. Treatment of staphylococcal septicemia with vancomycin: report of thirty-three cases. N Engl J Med 1960; 262: 49–55PubMedCrossRefGoogle Scholar
  34. 34.
    Downs NJ, Neihart RE, Dolezal JM, et al. Mild nephrotoxicity associated with vancomycin use. Arch Intern Med 1989; 149: 1777–81PubMedCrossRefGoogle Scholar
  35. 35.
    Farber BF, Moellering Jr RC. Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981. Antimicrob Agents Chemother 1983; 23: 138–41PubMedCrossRefGoogle Scholar
  36. 36.
    Rybak MJ, Albrecht LM, Boike SC, et al. Nephrotoxicity of vancomycin, alone and with an aminoglycoside. J Antimicrob Chemother 1990; 25: 679–87PubMedCrossRefGoogle Scholar
  37. 37.
    Dean RP, Wagner DJ, Tolpin MD. Vancomycin/aminoglycoside nephrotoxicity [letter]. J Pediatr 1985; 106: 861–2PubMedGoogle Scholar
  38. 38.
    Cimino MA, Rotstein C, Slaughter RL, et al. Relationship of serum antibiotic concentrations to nephrotoxicity in cancer patients receiving concurrent aminoglycoside and vancomycin therapy. Am J Med 1987; 83: 1091–7PubMedCrossRefGoogle Scholar
  39. 39.
    Zimmermann AE, Katona BG, Plaisance KL. Association of vancomycin serum concentrations with outcomes in patients with gram-positive bacteremia. Pharmacotherapy 1995; 15(1): 85–91PubMedGoogle Scholar
  40. 40.
    Pauly DJ, Musa DM, Lestico MR, et al. Risk of nephrotoxicity with combination vancomycin — aminoglycoside antibiotic therapy. Pharmacotherapy 1990; 10: 378–82PubMedGoogle Scholar
  41. 41.
    Goetz MB, Sayers J. Nephrotoxicity of vancomycin and aminoglycoside therapy separately and in combination. J Antimicrob Chemother 1993; 32: 325–34PubMedCrossRefGoogle Scholar
  42. 42.
    Polk RE, Healy DP, Schwartz LB, et al. Vancomycin and the red-man syndrome: pharmacodynamics of histamine release. J Infect Dis 1988; 157: 502–7PubMedCrossRefGoogle Scholar
  43. 43.
    Mackett RL, Guay DRP. Vancomycin-induced neutropenia. Can Med Assoc J 1985; 132: 39–40PubMedGoogle Scholar
  44. 44.
    Henry K, Steinberg I, Crossley KB. Vancomycin-induced neutropenia during treatment of osteomyelitis in an outpatient. Drug Intell Clin Pharm 1986; 20: 783–5PubMedGoogle Scholar
  45. 45.
    Koo KB, Bachand RL, Chow AW. Vancomycin — induced neutropenia. Drug Intell Clin Pharm 1986; 20: 780–2PubMedGoogle Scholar
  46. 46.
    Brown DL, Mauro LS. Vancomycin dosing chart for use in patients with renal impairment. Am J Kidney Dis 1988; 11: 15–9PubMedGoogle Scholar
  47. 47.
    Lake KD, Peterson CD. A simplified dosing method for initiating vancomycin therapy. Pharmacotherapy 1985; 5: 340–4PubMedGoogle Scholar
  48. 48.
    Matzke GR, McGory RW, Halstenson CE, et al. Pharmacokinetics of vancomycin in patients with various degrees of renal function. Antimicrob Agents Chemother 1984; 25: 433–7PubMedCrossRefGoogle Scholar
  49. 49.
    Moellering Jr RC, Krogstad DJ, Greenblatt DJ. Vancomycin therapy in patients with impaired renal function: a nomogram for dosage. Ann Intern Med 1981; 94: 343–6PubMedGoogle Scholar
  50. 50.
    Nielsen HE, Hansen HE, Korsager B, et al. Renal excretion of vancomycin in kidney disease. Acta Med Scand 1975; 197: 261–4PubMedCrossRefGoogle Scholar
  51. 51.
    Rodvold KA, Blum RA, Fischer JH, et al. Vancomycin pharmacokinetics in patients with various degrees of renal function. Antimicrob Agents Chemother 1988; 32: 848–52PubMedCrossRefGoogle Scholar
  52. 52.
    Rotschafer JC, Crossley K, Zaske DE, et al. Pharmacokinetics of vancomycin: observations in 28 patients and dosage recommendations. Antimicrob Agents Chemother 1982; 22: 391–4PubMedCrossRefGoogle Scholar
  53. 53.
    Tsubaki T, Goodin S, Leader WG, et al. Estimation of creatinine clearance in patients with gynecologic cancer. Clin Pharm 1993; 12: 685–90PubMedGoogle Scholar
  54. 54.
    Mcdermott DF, Galindo A, Sherman RL, et al. Inadequacy of predicted creatinine clearance as guide to chemotherapy. Cancer Treat Rep 1987; 71: 1067–9PubMedGoogle Scholar
  55. 55.
    Papadakis MA, Arieff AII. Unpredictability of clinical evaluation of renal function in cirrhosis. Am J Med 1987; 82: 945–52PubMedCrossRefGoogle Scholar
  56. 56.
    Soto J, Alsar MJ, Chantai P, et al. Correlation of vancomycin clearance and creatinine clearance: unreliability for predicting initial dosing in neutropenic heamatological patients [letter]. J Antimicrob Chemother 1993; 32: 920–2PubMedCrossRefGoogle Scholar
  57. 57.
    Birt JK, Chandler MHH. Using clinical data to determine vancomycin dosing parameters. Ther Drug Monit 1990; 12: 206–9PubMedCrossRefGoogle Scholar
  58. 58.
    Sawchuk RJ, Zaske DE. Pharmacokinetics of dosing regimens which utilize multiple intravenous infusions: gentamicin in burn patients. J Pharmacokinet Biopharm 1976; 4: 183–95PubMedGoogle Scholar
  59. 59.
    Burton ME, Gentle DL, Vasko MR. Evaluation of a Bayesian method for predicting vancomycin dosing. Drug Intell Clin Pharm 1989; 23: 294–300Google Scholar
  60. 60.
    Ito MK, Duren LL, Simonian JS, et al. Computer dosing program for the initiation of vancomycin therapy. Clin Pharm 1993; 12: 126–30PubMedGoogle Scholar
  61. 61.
    Wragge TM, Cooper BE. Correlation of aminoglycoside and vancomycin pharmacokinetic parameters. Ann Pharmacother 1993; 27: 1346–8PubMedGoogle Scholar
  62. 62.
    Welch LP, Leader WG, Chandler MHH. Predicting vancomycin pharmacokinetics by using aminoglycoside pharmacokinetics. Clin Pharm 1993; 12: 909–13PubMedGoogle Scholar
  63. 63.
    Rybak MJ, Boike SC. Individualized adjustment of vancomycin dosage: comparison with two dosage nomograms. Drug Intell Clin Pharm 1986; 20: 64–8PubMedGoogle Scholar
  64. 64.
    Ackerman BH, Olsen KM, Padilla CB. Errors in assuming a one-compartment model for vancomycin [letter]. Ther Drug Monit 1990; 12: 304–5PubMedCrossRefGoogle Scholar
  65. 65.
    Garrelts JC, Godley PJ, Horton MW, et al. Accuracy of Bayesian, Sawchuk-Zaske, and nomogram dosing methods for vancomycin. Clin Pharm 1987; 6: 795–9PubMedGoogle Scholar
  66. 66.
    Rodvold KA, Pryka RD, Garrison M, et al. Evaluation of a two-compartment Bayesian forecasting program for predicting vancomycin concentrations. Ther Drug Monit 1989; 11: 269–75PubMedCrossRefGoogle Scholar
  67. 67.
    Rodvold KA, Rotschafer JC, Gilliland SS, et al. Bayesian forecasting of serum vancomycin concentrations with nonsteady-state sampling strategies. Ther Drug Monit 1994; 16: 37–41PubMedCrossRefGoogle Scholar
  68. 68.
    Hurst AK, Yoshinaga MA, Mitani GH, et al. Application of a Bayesian method to monitor and adjust vancomycin dosage regimens. Antimicrob Agents Chemother 1990; 34: 1165–71PubMedCrossRefGoogle Scholar
  69. 69.
    Pryka RD, Rodvold KA, Garrison M, et al. Individualizing vancomycin dosage regimens: one-versus two-compartment Bayesian models. Ther Drug Monit 1989; 11: 450–4PubMedGoogle Scholar
  70. 70.
    del Mar Fernández de Gatta M, Fruns I, Domínguez-Gil A. Individualizing vancomycin dosing regimens: an evaluation of two pharmacokinetic dosing programs in critically ill patients. Pharmacotherapy. 1994; 14: 196–201Google Scholar
  71. 71.
    Wandstrat TL, Phelps SJ. Vancomycin dosing in neonatal patients: the controversy continues. Neonatal Netw 1994; 13: 33–9PubMedGoogle Scholar
  72. 72.
    Luer MS, Hatton J. Vancomycin administration into the cerebral spinal fluid: a review. Ann Pharmacother 1993; 27: 912–21PubMedGoogle Scholar
  73. 73.
    Blouin RA, Bauer LA, Miller DD, et al. Vancomycin pharmacokinetics in normal and morbidly obese subjects. Antimicrob Agents Chemother 1982; 21: 575–80PubMedCrossRefGoogle Scholar
  74. 74.
    Vance-Bryan K, Guay DRP, Gilliland SS, et al. Effect of obesity on vancomycin pharmacokinetic parameters as determined by using a Bayesian forecasting technique. Antimicrob Agents Chemother 1993; 37: 436–40PubMedCrossRefGoogle Scholar
  75. 75.
    Pollard TA, Lampasona V, Akkerman S, et al. Vancomycin redistribution: dosing recommendations following high-flux hemodialysis. Kidney Int 1994; 45: 232–7PubMedCrossRefGoogle Scholar
  76. 76.
    Debock V, Verbeelen D, Maes V, et al. Pharmacokinetics of vancomycin in patients undergoing hemodialysis and hemofiltration. Nephrol Dial Transplant 1989; 4: 636–9Google Scholar
  77. 77.
    Lanese DM, Alfrey PS, Molitoris BA. Markedly increased clearance of vancomycin during hemodialysis using polysulfone dialyzers. Kidney Int 1989; 35: 1409–12PubMedCrossRefGoogle Scholar
  78. 78.
    Torras J, Cao C, Rivas MC, et al. Pharmacokinetics of vancomycin in patients undergoing dialysis with polyacrylonitrile. Clin Nephrol 1991; 36: 35–41PubMedGoogle Scholar
  79. 79.
    Bönier J, Reetze-Bonorden P, Keller E, et al. Rebound of plasma vancomycin levels after hemodialysis with highly permeable membranes. Eur J Clin Pharmacol 1992; 42: 635–40Google Scholar
  80. 80.
    Desoi CA, Sahm DF, Umans JG. Vancomycin elimination during high-flux hemodialysis: kinetic model and comparisons of four membranes. Am J Kidney Dis 1992; 20: 354–60PubMedGoogle Scholar
  81. 81.
    Anne L, Hu M, Chan K, et al. Potential problem with fluorescence polarization immunoassay cross-reactivity to vancomycin degradation product CDP-1: its detection in sera of renally impaired patients. Ther Drug Monit 1989; 11: 585–91PubMedCrossRefGoogle Scholar
  82. 82.
    Hu MW, Anne L, Forni T, et al. Measurement of vancomycin in renally impaired patient samples using a new high-performance liquid chromatography method with vitamin B12 internal standard: comparison of high-performance liquid chromatography, EMIT, and fluorescence polarization immunoassay methods. Ther Drug Monit. 1990; 12: 562–9PubMedCrossRefGoogle Scholar
  83. 83.
    Morse GD, N’airn DK, Bertino JS, et al. Overestimation of vancomycin concentrations utilizing fluorescence polarization immunoassay in patients on peritoneal dialysis. Ther Drug Monit 1987; 9: 212–5PubMedCrossRefGoogle Scholar
  84. 84.
    Perino LM, Mueller BA. Accuracy of vancomycin serum concentrations in patients with renal failure. Ann Pharmacother 1993; 27: 892–3PubMedGoogle Scholar
  85. 85.
    del Mar Fernández de Gatta M, Fruns I, Hernández JM, et al. Vancomycin pharmacokinetics and dosage requirements in hematologic malignancies. Clin Pharm 1993; 12: 515–20Google Scholar
  86. 86.
    Rybak MJ, Albrecht LM, Berman JR, et al. Vancomycin pharmacokinetics in burn patients and intravenous drug abusers. Antimicrob Agents Chemother 1990; 34: 792–5PubMedCrossRefGoogle Scholar
  87. 87.
    Rice TL. Simplified dosing and monitoring of vancomycin for the burn care clinician. Burns 1992; 18: 355–61PubMedCrossRefGoogle Scholar
  88. 88.
    Garrelts JC, Peterie JD. Altered vancomycin dose vs. serum concentration relationship in burn patients. Clin Pharmacol Ther 1988; 44: 9–13PubMedCrossRefGoogle Scholar
  89. 89.
    Fraser GL, D’Amato S. Vancomycin pharmacokinetics in elderly patients [letter]. Clin Pharm 1993; 12: 481PubMedGoogle Scholar
  90. 90.
    Guay DRP, Vance-Bryan K, Gilliland S, et al. Comparison of vancomycin pharmacokinetics in hospitalized elderly and young patients using a Bayesian forecaster. J Clin Pharmacol 1993; 33: 918–22PubMedGoogle Scholar
  91. 91.
    Leonard AE, Boro MS. Vancomycin pharmacokinetics in middle-aged and elderly men. Am J Hosp Pharm 1994; 51: 798–800PubMedGoogle Scholar
  92. 92.
    Moellering Jr RC. Monitoring serum vancomycin levels: climbing the mountain because it is there [editorial]. Clin Infect Dis 1994; 18: 544–6PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1995

Authors and Affiliations

  • W. Greg Leader
    • 1
  • Mary H. H. Chandler
    • 2
    • 3
  • Mary Castiglia
    • 1
  1. 1.Department of Clinical Pharmacy, School of PharmacyWest Virginia UniversityMorgantownUSA
  2. 2.Pharmacy Practice and Science, College of PharmacyUniversity of KentuckyUSA
  3. 3.Clinical Pharmacokinetics ServiceUniversity of Kentucky Medical CenterLexingtonUSA

Personalised recommendations